Antidepressant-Free: The Surprising Truth About Quitting Without Therapy (M) PsyBlog
J&J seeks expanded approval for antidepressant Spravato BioPharma Dive
Johnson & Johnson (JNJ) seeks U.S. FDA approval of SPRAVATO as the first and only monotherapy for adults with treatment-resistant depression StreetInsider.com
Johnson & Johnson (JNJ) seeks U.S.
Simple supports help some taper off antidepressants The Medical Republic
Sage Therapeutics/Biogen’s episodic therapy zuranolone could change MDD treatment Yahoo Finance
